Natco Pharma seeks emergency nod for its COVID-19 capsules; rises over 6 per cent

Natco Pharma seeks emergency nod for its COVID-19 capsules; rises over 6 per cent

Abhinav Lahoti
/ Categories: Trending, Mindshare

The company today announced that it has applied to Central Drugs Standard Control Organisation (CDSCO) of India for the approval of phase 3 clinical trials of ‘Molnupiravir’ capsules, which have shown promising results during the treatment of COVID-19 positive patient.  

The pre-clinical data has shown that the capsule has broad anti-influenza activity, which includes highly potent inhibition of SARS-CoV-2 replication. During its pre-clinical trials, the patients treated with this capsule achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short. It also has the additional advantage of being an oral therapy.  

The company is hoping that CDSCO would give their drug an emergency approval based on “compassionate use” for patients. This kind of approval is given for investigational drugs so, a patient with an immediately life-threatening condition can gain access to the drug. The company is ready to launch the product this month if it gains approval from CDSCO.  

At 10.30 am on Monday, its share price was trading 6.25 per cent higher at Rs 932.70 on BSE.

Previous Article In conversation with Mahesh Patil, Chief Investment Officer of Aditya Birla Sun Life AMC Ltd
Next Article Biocon Biologics and its partner Viatris get EC nod for biosimilar Bevacizumab
Rate this article:
3.8

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR